New drug offers hope for rare, severe high-triglyceride conditions
NCT ID NCT06796426
First seen Jan 09, 2026 · Last updated May 02, 2026 · Updated 14 times
Summary
This program provides plozasiran to people with familial chylomicronemia syndrome (FCS) or severe high triglycerides (SHTG) who are not well-controlled on standard treatments. Participants receive injections every 3 months for 15-21 months. The goal is to lower triglyceride levels and reduce the risk of pancreatitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arrowhead Pharmaceuticals, Inc.
AVAILABLEPasadena, California, 91105, United States
Conditions
Explore the condition pages connected to this study.